May is National Mental Health Month and with the global pandemic focusing on self-health and controlling anxiety during this time is essential. Announced this week, Lief Therapeutics’ Downtime™ digital anxiety intervention is now available as an adjunct treatment for Generalized Anxiety Disorder during the COVID-19 emergency. The patented digital intervention is delivered through the company’s flagship Lief Rx Smart Patch, a wearable ECG device now covered under most insurance plans.
For the duration of the COVID-19 emergency, physicians can prescribe Downtime™ to help patients manage symptoms of anxiety in conjunction with their primary treatment plan.
Lief’s digital prescriptions are designed to improve heart rate variability (HRV), the gold standard biomarker for mental health. A meta-analysis of 2,086 anxiety patients found that low HRV is associated with anxiety disorders, including generalized anxiety disorder, social anxiety, PTSD, and panic. Lief’s core offering, HRV biofeedback training, has been shown to significantly decrease stress and anxiety.
In clinical trials, 88% of Lief study participants reported significantly reduced anxiety over the course of eight weeks, as measured by standardized psychometric assessment. Participants were also able to significantly increase their HRV by approximately 50% in 3 minute exercises with the device.
The Lief Rx Smart Patch can be worn discreetly throughout the day to help patients track their HRV and train it higher through personalized biofeedback exercises. Healthcare providers can use Lief’s free Clinician Dashboard to remotely enroll eligible patients in the Lief program, monitor their biomarker and self-report data, and send secure chat and video messages through the connected mobile app.
Lief’s fully remote program helps providers treat patients’ anxiety and communicate outside the office, thereby supporting nationwide social distancing measures. By enabling patients to reduce their anxiety through empowering biofeedback exercises and support from a remote behavioral health specialist, Lief extends the capabilities of care teams and helps ease the burden on health care facilities and providers.
Highlighting the growing need for remote mental health technologies like Lief in light of ongoing social isolation during COVID-19, the FDA noted in their updated policy guidance:
“The use of digital health technologies, including software as a medical device or other digital therapeutics solutions, may improve mental health and well-being of patients with psychiatric conditions during periods of shelter-in-place, isolation, and quarantine.”-U.S. Department of Health and Human Services, Food and Drug Administration,
Center for Devices and Radiological Health, & Office of Product Evaluation and Quality
As a result of the updated policy guidance, patients can utilize Lief to further reduce their anxiety as a complement to talk therapy, their medication regimen, or another primary therapy as determined by their physician. The wearability and continuous monitoring capabilities of Lief offer a valuable tool for those in need of mental health support on a regular basis.
Whether utilized in between appointments with their doctor as a routine well-being practice, or in response to acutely stressful events, Lief offers a flexible adjunct treatment option for those suffering from generalized anxiety disorder, who need more support during this challenging time.
Lief Therapeutics is currently offering 10% off new users’ first month’s subscription to its direct to consumer telemedicine services with code NEWYEARSLIEF10. For more information, visit www.getlief.com.
Source: Lief Therapeutics